Post-earnings recap
Reported
Thu, Apr 30, 2026
EPS actual
$1.99
EPS est.
$0.91
EPS surprise
+117.96%
1-day move
+2.76%
Alnylam Pharmaceuticals reported a strong earnings per share, significantly exceeding expectations, which led to a positive stock reaction of 2.76%. However, the lack of revenue data and management commentary leaves some uncertainty about the overall financial health and future direction of the company.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.99 | $1.48 | +117.96% |
| Revenue | N/A | $1.1B | N/A |
No transcript is on record, and the analysis is based solely on numerical results.
Alnylam Pharmaceuticals, Inc. is a biotechnology company focused on developing therapies based on RNA interference to treat genetic diseases. With a market cap of $40 billion, it plays a significant role in the health care sector, particularly in innovative treatments that address unmet medical needs.
Last quarter
In the last quarter, Alnylam reported an EPS of $1.25, significantly beating expectations of $0.75. However, the stock declined by 4.28% the following day, indicating some investor caution despite the positive earnings surprise.
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+142.32%
Avg 1-day reaction
-3.73%
Analysts are generally optimistic about Alnylam's upcoming earnings, expecting solid EPS and revenue growth. However, the stock's recent performance suggests that investors may be cautious about future guidance.
Bull case
If Alnylam exceeds the EPS estimate and shows strong revenue growth, it could boost investor confidence and lead to a positive stock reaction.
Bear case
Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a significant drop in the stock price.
Key metrics to watch
EPS
$1.48Earnings per share is a key indicator of profitability and can influence investor sentiment.
Revenue
$1.1BRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Alnylam achieve an EPS of at least $1.48?
This figure is crucial as it sets the benchmark for investor expectations and could significantly impact stock performance.
Q2
What guidance will management provide for future revenue growth?
Future revenue guidance will help investors gauge the company's growth trajectory and market potential.
—
Est. EPS
$0.76
Est. Rev
$17.1B
Impl. Move
±2.9%
Why consensus could be wrong
The Street may be underestimating Alnylam's ability to deliver strong EPS growth due to its recent performance trends and product pipeline advancements.
Supporting evidence
The company has consistently beaten EPS estimates in the past quarters, indicating a strong operational track record.
Options pricing suggests a higher expected move than historical averages, indicating potential for a significant surprise.
Key risk
If Alnylam's EPS comes in below $1.48, it could lead to a reassessment of its growth potential.
Pre-commit to what would confirm each case.
The market is debating whether Alnylam can sustain its recent earnings momentum amid competitive pressures and market conditions.
Bull confirmed if
An EPS of $1.60 or higher would confirm the bull case, indicating strong operational performance.
Bear confirmed if
An EPS below $1.16 would confirm the bear case, suggesting potential challenges in meeting market expectations.
What the market is pricing for the move.
Implied Move
±7.38%
Historical Avg
±8.3%
The options market is pricing in a relatively large move, suggesting that investors anticipate volatility around the earnings report.
Options are pricing ±7.4% while ALNY has averaged ±8.3% over the last 8 prints — setup is roughly in line with history.
ATM IV
0.5%
30d HV
39.7%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 7 of 23 (30%)
This setup has occurred 30 times across Health Care in the last 2 years. 16 of 23 (70%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 4.2%, with a raw directional average of +0.6% (modestly positive historical bias).
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$398,855.04
1,758 sh
1 insider
Net
$398,855.04
Net selling
Most Active Insiders· 1 open-market trade
$398,855.04
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
101.65%
of float
Insider
0.18%
of float
Holders
1,194
institutions
Top Holders· as of Jun 2026
FMR, LLC
15,023,962 sh · $3.4B
11.23%
3.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Alnylam beats expectations and raises guidance, history suggests the stock could rise by around 1.13% on the following day.
In line / cautious
If results are in line with expectations but management is cautious, the stock may experience muted movement as investors reassess future growth.
Miss
If the company misses earnings expectations, history suggests a potential decline of around 1.13% or more, reflecting investor disappointment.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
0 buys·1 sell
Members
1
Senate only
Est. Notional
$1,001.00–$15,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Recent Transactions
Oct 2, 2026 · @ $226.88
1,758 sh
$398,855.04
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Capital World Investors
11,144,846 sh · $2.5B
8.33%
3.2%
Blackrock Inc.
10,907,675 sh · $2.4B
8.15%
4.4%
Capital Research Global Investors
9,750,699 sh · $2.2B
7.29%
2.9%
Vanguard Portfolio Management LLC
6,538,390 sh · $1.5B
4.89%
0.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
Recent Transactions
Traded Aug 11, 2026 · disclosed Sep 9, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.